

AMENDMENTS TO THE CLAIMS


This listing of claims will replace all prior versions, and listing of claims in the application.


1. Cancel


2. Cancel.


3. Cancel.


4(Once Amended). A method of binding the $\alpha_2\delta$ subunit of voltage gated calcium channels comprising a step of administering to a patient in need thereof an effective amount of a compound represented by Formula (I) selected from:



























































or a pharmaceutically acceptable salt thereof.

5. Cancel

6. Cancel.

7. Cancel.

8. Cancel

9. Cancel.

10. Cancel.

11. Cancel

12. Cancel.

13. Cancel.

14. Cancel

15. Cancel.

16. Cancel.

17. Cancel

18. Cancel.

19. Cancel.

20. Cancel


21. Cancel.


22. Cancel.


23. Cancel


24. Cancel.


25 (Original). A compound selected from:




























































or a pharmaceutically acceptable salt thereof.

26 (Currently Amended). A compound represented by Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein

R¹ is -C₀₋₆alkyl-aryl, -C₀₋₆alkyl-heteroaryl, -C₀₋₆alkyl-C₃₋₆cycloalkyl, or -C₀₋₆alkyl-heteroC₃₋₇cycloalkyl, optionally substituted with 1-6 independent halogen, -CN, NO₂, -C₁₋₆alkyl, -C₀₋₆alkyl-C₃₋₆cycloalkyl, -C₀₋₆alkyl-heteroC₃₋₇cycloalkyl, -OR⁶, -NR⁶R⁷, -C(=NR⁶)NR⁷R⁸, -N(-NR⁸⁸R⁶)NR⁷R⁸, -NR⁶COR⁷, -NR⁶CO₂R⁷, -NR⁶SO₂R⁸⁸, -NR⁶CONR⁷R⁸, -SR⁸⁸, -SOR⁸⁸, -SO₂R⁸⁸, -SO₂NR⁶R⁷, -COR⁶, -CO₂R⁶, -CONR⁶R⁷, -C(=NR⁶)R⁷, or -C(=NOR⁶)R⁷ substituents;

R², and R³, each independently is -C₁₋₆alkyl, -C₀₋₆alkyl-aryl, -C₀₋₆alkyl-heteroaryl, -C₀₋₆alkyl-C₃₋₆cycloalkyl, or -C₀₋₆alkyl-heteroC₃₋₇cycloalkyl, optionally substituted with 1-6 independent halogen, -CN, NO₂, -C₁₋₆alkyl, -OR⁶, -NR⁶R⁷, -C(=NR⁶)NR⁷R⁸, -N(-NR⁸⁸R⁶)NR⁷R⁸, -NR⁶COR⁷, -NR⁶CO₂R⁷, -NR⁶SO₂R⁸⁸, -NR⁶CONR⁷R⁸, -SR⁸⁸, -SOR⁸⁸, -SO₂R⁸⁸, -SO₂NR⁶R⁷, -COR⁶, -CO₂R⁶, -CONR⁶R⁷, -C(=NR⁶)R⁷, or -C(=NOR⁶)R⁷ substituents;

R², R⁴, R³, and R⁵ each independently is -C₀₋₆alkyl, -C₀₋₆alkyl-aryl, -C₀₋₆alkyl-heteroaryl, -C₀₋₆alkyl-C₃₋₆cycloalkyl, or -C₀₋₆alkyl-heteroC₃₋₇cycloalkyl, optionally substituted with 1-6 independent halogen, -CN, NO₂, -C₁₋₆alkyl, -OR⁶, -NR⁶R⁷, -C(=NR⁶)NR⁷R⁸, -N(-NR⁸⁸R⁶)NR⁷R⁸, -NR⁶COR⁷, -NR⁶CO₂R⁷, -NR⁶SO₂R⁸⁸, -

NR₆CONR⁷R⁸, -SR⁸⁸, -SOR⁸⁸, -SO₂R⁸⁸, -SO₂NR⁶R⁷, -COR⁶, -CO₂R⁶, -CONR⁶R⁷, -C(=NR⁶)R⁷, or -C(=NOR⁶)R⁷ substituents; and

R⁶, R⁷, R⁸, and R⁸⁸ each independently is -C₀-6alkyl, -C₃-7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C₁-6alkyl, -O(C₀-6alkyl), -O(C₃-7cycloalkyl), -O(aryl), -N(C₀-6alkyl)(C₀-6alkyl), -N(C₀-6alkyl)(C₃-7cycloalkyl), or -N(C₀-6alkyl)(aryl) substituents, wherein when the carbon atom in -C₀-6alkyl equals "0" then no alkyl is present; provided that the compound is not

6-methyl-6*H*-pyrrolo[3,4-*d*]pyridazine,

1,4,5,7-tetramethyl-6-phenyl-6*H*-pyrrolo[3,4-*d*]pyridazine,

1,4,5-trimethyl-6,7-diphenyl-6*H*-pyrrolo[3,4-*d*]pyridazine,

5,7-dimethyl-1,4,6-triphenyl-6*H*-pyrrolo[3,4-*d*]pyridazine,

5-methyl-1,4,6,7-tetraphenyl-6*H*-pyrrolo[3,4-*d*]pyridazine,

1,4-bis-(4-methoxy-phenyl)-5,7-dimethyl-6-phenyl-6*H*-pyrrolo[3,4-

d]

1,4-bis-(4-methoxy-phenyl)-5-methyl-6,7-diphenyl-6*H*-pyrrolo[3,4-*d*]

1,4-diethyl-5,7-dimethyl-6-phenyl-6*H*-pyrrolo[3,4-*d*]pyridazine,

1,4,5,7-tetramethyl-6*H*-pyrrolo[3,4-*d*]pyridazine,

N-(1,4,5,7-tetramethyl-pyrrolo[3,4-*d*]pyridazin-6-yl)-benzamide,

1,4,5,7-tetramethyl-pyrrolo[3,4-*d*]pyridazin-6-ylamine picrate,

1,4,5,7-tetramethyl-pyrrolo[3,4-*d*]pyridazin-6-ylamine,

5,7-dimethyl-6-phenyl-6*H*-pyrrolo[3,4-*d*]pyridazine,

5,7-dimethyl-2-phenacyl-6*H*-pyrrolo[3,4-*d*]pyridazinium bromide,

2-(2-methoxycarbonylvinyl)-5,7-dimethyl-6*H*-pyrrolo[3,4-*d*]pyridazinium

tetrafluoroborate

5,7-diphenyl-6*H*-pyrrolo[3,4-*d*]pyridazine,

5,6,7-trimethyl-6*H*-pyrrolo[3,4-*d*]pyridazine,

1,4-diphenyl-7,8,9,10-tetrahydro-pyridazino[4,5-*a*]indolizine,

5-methyl-1,4-diphenyl-7,8,9,10-tetrahydro-pyridazino[4,5-*a*]indolizine,

6-benzyl-1,4-diphenyl-5-p-tolyl-6*H*-pyrrolo[3,4-*d*]pyridazine,

6-benzyl-5-(2-chloro-phenyl)-1,4-diphenyl-6*H*-pyrrolo[3,4-*d*]pyridazine,

1,4,5,6,7-pentaphenyl-6*H*-pyrrolo[3,4-*d*]pyridazine,

6,7,10,11-tetraphenyl-pyridazino[4',5':3,4]pyrrolo[1,2-*a*]quinoxaline,

11-(4-nitro-phenyl)-6,7,10-triphenyl-pyridazino[4',5':3,4]pyrrolo[1,2-

a]

6-benzyl-1,4,5-triphenyl-6*H*-pyrrolo[3,4-*d*]pyridazine,


9,12-diphenyl-pyridazino[4',5':3,4]pyrrolo[2,1-*a*]isoquinoline,
5-methylsulfanyl-1,4,6,7-tetraphenyl-6*H*-pyrrolo[3,4-*d*]pyridazine,
1,4,6,7-tetraphenyl-6*H*-pyrrolo[3,4-*d*]pyridazine-5-carboxylic acid ethyl ester,
7,10-diphenyl-pyridazino[4',5':3,4]pyrrolo[1,2-*a*]quinoline,
11,14-diphenyl-pyridazino[4',5':3,4]pyrrolo[1,2-*f*]phenanthridine,
1-oxo-7-oxy-6*b*,11*b*-dihydro(pyridazino[4',5'-*c*]-pyrrolo)[2,1-*c*]benzoxazine-
1,4,
10-methyl-1,4-diphenyl-8,9-dihydro-7*H*-benzo(*ef*)pyridazino[4,5-
a]cycl[3.3.2]azine,
11-methyl-1,4-diphenyl-7,8,9,10-tetrahydrocyclohepta(*ef*)pyridazino[4,5-
a]cycl[3.3.2]azine,
1,4-dichloro-5,6,7-trimethyl-6*H*-pyrrolo[3,4-*d*]pyridazine,
1-chloro-4-ethoxy-5,6,7-trimethyl-6*H*-pyrrolo[3,4-*d*]pyridazine,
1-chloro-5,6,7-trimethyl-6*H*-pyrrolo[3,4-*d*]pyridazinium chloride,
1-ethoxy-2,5,6,7-tetramethyl-6*H*-pyrrolo[3,4-*d*]pyridazinium
tetrafluoroborate,
1-ethoxy-5,6,7-trimethyl-2*H*,6*H*-pyrrolo[3,4-*d*]pyridazinium tetrafluoroborate,
1-ethoxy-3-ethyl-5,6,7-trimethyl-6*H*-pyrrolo[3,4-*d*]pyridazinium
tetrafluoroborate,
1-ethoxy-5,6,7-trimethyl-6*H*-pyrrolo[3,4-*d*]pyridazine,
5-cyano-1,4-dimethylpyridazino[4,5-*a*]indolizine,
1,4-dimethyl-6-phenyl-2,3,8*a*-triaza-fluorene-9-carbonitrile,
6-benzoyl-1,4-dimethyl-2,3,8*a*-triaza-fluorene-9-carbonitrile,
6-benzyl-1,4-diphenyl-2,3,8*a*-triaza-fluorene-9-carbonitrile,
1,4,6-trimethyl-2,3,8*a*-triaza-fluorene-9-carbonitrile,
5-cyano-1,4-diphenylpyridazino[4,5-*a*]indolizine,
6-methyl-1,4-diphenyl-2,3,8*a*-triaza-fluorene-9-carbonitrile,
6-benzoyl-1,4-diphenyl-2,3,8*a*-triaza-fluorene-9-carbonitrile,
1,4,6-triphenyl-2,3,8*a*-triaza-fluorene-9-carbonitrile,
5,7-dimethyl-1,4-diphenyl-2,3,8*a*-triaza-fluorene-9-carbonitrile,
9,12-diphenyl-pyridazino[4',5':3,4]pyrrolo[2,1-*a*]isoquinoline-8-carbonitrile,
dimethyl 3,12,13,17-tetramethyl-7²,7³-diazabeno[g]porphyrin-2,18-
dipropionate,
5,6-dihydro-2,3-dimethoxypyridazino[4',5':3,4]pyrrolo[2,1-*a*]isochinolin-9-
ol,

5,6-dihydro-2,3-dimethoxypyridazino[4',5':3,4]pyrrolo[2,1-*a*]isochinolin-9-ol-hydrochloride,

3-methyl-6,9-diphenylthiazolo[3',2':1,2]pyrrolo[3,4-*d*]pyridine, or
1,4-diphenylpyridazino[4',5':3,4]pyrrolo[2,1-*b*]benzothiazole; and
is not selected from the following table:

Amended Claims possibly to be rejoined:

1(Currently Amended). A method of binding the $\alpha 2\delta$ subunit of voltage gated calcium channels comprising a step of administering an effective amount of a compound represented by Formula (I):



(I)


or a pharmaceutically acceptable salt thereof, wherein


R¹ is -C₀₋₆alkyl-aryl, -C₀₋₆alkyl-heteroaryl, -C₀₋₆alkyl-C₃₋₆cycloalkyl, or -C₀₋₆alkyl-heteroC₃₋₇cycloalkyl, optionally substituted with 1-6 independent halogen, -CN, NO₂, -C₁₋₆alkyl, -C₀₋₆alkyl-C₃₋₆cycloalkyl, -C₀₋₆alkyl-heteroC₃₋₇cycloalkyl, -OR⁶, -NR⁶R⁷, -C(=NR⁶)NR⁷R⁸, -N(-NR⁸⁸R⁶)NR⁷R⁸, -NR⁶COR⁷, -NR⁶CO₂R⁷, -NR⁶SO₂R⁸⁸, -NR⁶CONR⁷R⁸, -SR⁸⁸, -SOR⁸⁸, -SO₂R⁸⁸, -SO₂NR⁶R⁷, -COR⁶, -CO₂R⁶, -CONR⁶R⁷, -C(=NR⁶)R⁷, or -C(=NOR⁶)R⁷ substituents;

R², R⁴, R³, and R⁵ each independently is -C₀₋₆alkyl, -C₀₋₆alkyl-aryl, -C₀₋₆alkyl-heteroaryl, -C₀₋₆alkyl-C₃₋₆cycloalkyl, or -C₀₋₆alkyl-heteroC₃₋₇cycloalkyl, optionally substituted with 1-6 independent halogen, -CN, NO₂, -C₁₋₆alkyl, -OR⁶, -NR⁶R⁷, -C(=NR⁶)NR⁷R⁸, -N(-NR⁸⁸R⁶)NR⁷R⁸, -NR⁶COR⁷, -NR⁶CO₂R⁷, -NR⁶SO₂R⁸⁸, -NR⁶CONR⁷R⁸, -SR⁸⁸, -SOR⁸⁸, -SO₂R⁸⁸, -SO₂NR⁶R⁷, -COR⁶, -CO₂R⁶, -CONR⁶R⁷, -C(=NR⁶)R⁷, or -C(=NOR⁶)R⁷ substituents; and

R⁶, R⁷, R⁸, and R⁸⁸ each independently is -C₀₋₆alkyl, -C₃₋₇cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C₁₋₆alkyl, -O(C₀₋₆alkyl), -O(C₃₋₇cycloalkyl), -O(aryl), -N(C₀₋₆alkyl)(C₀₋₆alkyl), -N(C₀₋₆alkyl)(C₃₋₇cycloalkyl), or -N(C₀₋₆alkyl)(aryl) substituents, wherein when the carbon atom in -C₀₋₆alkyl equals "0" then no alkyl is present; and

provided that the compound is not selected from the following table:








2(Original). The method according to Claim 1, wherein R¹ is -C₀₋₆alkyl-aryl.


3(Original). The method according to Claim 2, wherein R¹ is -C₀₋₆alkyl-phenyl.


4(Currently Amended). A method of binding the $\alpha_2\delta$ subunit of voltage gated calcium channels comprising a step of administering to a patient in need thereof an effective amount of a compound represented by Formula (I) selected from: The method according to Claim 1, wherein the compound is selected from:



























































or a pharmaceutically acceptable salt thereof.

5(Original). A method of treatment of neuropathic pain comprising a step of administering an effective amount of a pharmaceutical composition comprising: a therapeutically effective amount of the compound according to claim 1, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

6(Original). The method according to claim 5, wherein said composition further comprising i) an opiate agonist, ii) an opiate antagonist, iii) an mGluR5 antagonist, iv) a 5HT receptor agonist, v) a 5HT receptor antagonist, vi) a sodium channel antagonist, vii) an NMDA receptor agonist, viii) an NMDA receptor antagonist, ix) a COX-2 selective inhibitor, x) an NK1 antagonist, xi) a non-steroidal anti-inflammatory drug, xii) a GABA-A receptor modulator, xiii) a dopamine agonist, xiv) a dopamine antagonist, xv) a selective serotonin reuptake inhibitor, xvi) a tricyclic antidepressant drug, xvii) a norepinephrine modulator, xviii) L-DOPA, xix) buspirone, xx) a lithium salt, xxi) valproate, xxii) neurontin, xxiii) olanzapine, xxiv) a nicotinic agonist, xxv) a nicotinic antagonist, xxvi) a muscarinic agonist, xxvii) a muscarinic antagonist, xxviii) a selective serotonin and norepinephrine reuptake inhibitor (SSNRI), xxix) a heroin substituting drug, xxx) disulfiram, or xxxi) acamprosate.

7(Original). The method according to claim 6, wherein said heroin substituting drug is methadone, levo-alpha-acetylmethadol, buprenorphine or naltrexone.

8(Once Amended). A method of treatment of pain comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

9(Once Amended). A method of treatment of a pain disorder wherein said pain disorder is acute pain, persistent pain, chronic pain, inflammatory pain, or neuropathic pain, comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

10(Once Amended). A method of treatment of anxiety, depression, bipolar disorder, psychosis, drug withdrawal, tobacco withdrawal, memory loss, cognitive impairment, dementia, Alzheimer's disease, schizophrenia or panic comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

11(Once Amended). A method of treatment of disorders of extrapyramidal motor function comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

12(Original). The method of claim 11 wherein said disorder of extrapyramidal motor function is Parkinson's disease, progressive supramuscular palsy, Huntington's disease, Gilles de la Tourette syndrome, or tardive dyskinesia.

13(Once Amended). A method of treatment of anxiety disorders comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

14(Original). The method of claim 13 wherein said anxiety disorder is panic attack, agoraphobia or specific phobias, obsessive-compulsive disorders, post-traumatic stress disorder, acute stress disorder, generalized anxiety disorder, eating disorder, substance-induced anxiety disorder, or nonspecified anxiety disorder.

15(Once Amended). A method of treatment of neuropathic pain comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

16(Once Amended). A method of treatment of Parkinson's Disease comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

17(Once Amended). A method of treatment of depression comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

18(Once Amended). A method of treatment of epilepsy comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

19(Once Amended). A method of treatment of inflammatory pain comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

20(Once Amended). A method of treatment of cognitive dysfunction comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.


21(Once Amended). A method of treatment of drug addiction, drug abuse and drug withdrawal comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.


22(Once Amended). A method of treatment of bipolar disorders comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.


23(Once Amended). A method of treatment of circadian rhythm and sleep disorders comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.


24(Original). The method of Claim 23 wherein the circadian rhythm and sleep disorders are shift-work induced sleep disorder or jet-lag.


25 (Original). A compound selected from:




























































or a pharmaceutically acceptable salt thereof.

26 (Currently Amended). A compound represented by Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein

R¹ is -C₀₋₆alkyl-aryl, -C₀₋₆alkyl-heteroaryl, -C₀₋₆alkyl-C₃₋₆cycloalkyl, or -C₀₋₆alkyl-heteroC₃₋₇cycloalkyl, optionally substituted with 1-6 independent halogen, -CN, NO₂, -C₁₋₆alkyl, -C₀₋₆alkyl-C₃₋₆cycloalkyl, -C₀₋₆alkyl-heteroC₃₋₇cycloalkyl, -OR⁶, -NR⁶R⁷, -C(=NR⁶)NR⁷R⁸, -N(-NR⁸⁸R⁶)NR⁷R⁸, -NR⁶COR⁷, -NR⁶CO₂R⁷, -NR⁶SO₂R⁸⁸, -NR⁶CONR⁷R⁸, -SR⁸⁸, -SOR⁸⁸, -SO₂R⁸⁸, -SO₂NR⁶R⁷, -COR⁶, -CO₂R⁶, -CONR⁶R⁷, -C(=NR⁶)R⁷, or -C(=NOR⁶)R⁷ substituents;

R², and R³, each independently is -C₁₋₆alkyl, -C₀₋₆alkyl-aryl, -C₀₋₆alkyl-heteroaryl, -C₀₋₆alkyl-C₃₋₆cycloalkyl, or -C₀₋₆alkyl-heteroC₃₋₇cycloalkyl, optionally substituted with 1-6 independent halogen, -CN, NO₂, -C₁₋₆alkyl, -OR⁶, -NR⁶R⁷, -C(=NR⁶)NR⁷R⁸, -N(-NR⁸⁸R⁶)NR⁷R⁸, -NR⁶COR⁷, -NR⁶CO₂R⁷, -NR⁶SO₂R⁸⁸, -NR⁶CONR⁷R⁸, -SR⁸⁸, -SOR⁸⁸, -SO₂R⁸⁸, -SO₂NR⁶R⁷, -COR⁶, -CO₂R⁶, -CONR⁶R⁷, -C(=NR⁶)R⁷, or -C(=NOR⁶)R⁷ substituents;

R², R⁴, R³, and R⁵ each independently is -C₀₋₆alkyl, -C₀₋₆alkyl-aryl, -C₀₋₆alkyl-heteroaryl, -C₀₋₆alkyl-C₃₋₆cycloalkyl, or -C₀₋₆alkyl-heteroC₃₋₇cycloalkyl, optionally substituted with 1-6 independent halogen, -CN, NO₂, -C₁₋₆alkyl, -OR⁶, -NR⁶R⁷, -C(=NR⁶)NR⁷R⁸, -N(-NR⁸⁸R⁶)NR⁷R⁸, -NR⁶COR⁷, -NR⁶CO₂R⁷, -NR⁶SO₂R⁸⁸, -NR⁶CONR⁷R⁸, -SR⁸⁸, -SOR⁸⁸, -SO₂R⁸⁸, -SO₂NR⁶R⁷, -COR⁶, -CO₂R⁶, -CONR⁶R⁷, -C(=NR⁶)R⁷, or -C(=NOR⁶)R⁷ substituents; and

R⁶, R⁷, R⁸, and R⁸⁸ each independently is -C₀₋₆alkyl, -C₃₋₇cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C₁₋₆alkyl, -O(C₀₋₆alkyl), -O(C₃₋₇cycloalkyl), -O(aryl), -N(C₀₋₆alkyl)(C₀₋₆alkyl), -N(C₀₋₆alkyl)(C₃₋₇cycloalkyl), or -N(C₀₋₆alkyl)(aryl) substituents, wherein when the carbon atom in -C₀₋₆alkyl equals "0" then no alkyl is present; provided that the compound is not

6-methyl-6H-pyrrolo[3,4-d]pyridazine,
1,4,5,7-tetramethyl-6-phenyl-6H-pyrrolo[3,4-d]pyridazine,
1,4,5-trimethyl-6,7-diphenyl-6H-pyrrolo[3,4-d]pyridazine,
5,7-dimethyl-1,4,6-triphenyl-6H-pyrrolo[3,4-d]pyridazine,
5-methyl-1,4,6,7-tetraphenyl-6H-pyrrolo[3,4-d]pyridazine,

1,4-bis-(4-methoxy-phenyl)-5,7-dimethyl-6-phenyl-6*H*-pyrrolo[3,4-*d*]pyridazine,
1,4-bis-(4-methoxy-phenyl)-5-methyl-6,7-diphenyl-6*H*-pyrrolo[3,4-*d*]pyridazine,
1,4-diethyl-5,7-dimethyl-6-phenyl-6*H*-pyrrolo[3,4-*d*]pyridazine,
1,4,5,7-tetramethyl-6*H*-pyrrolo[3,4-*d*]pyridazine,
N-(1,4,5,7-tetramethyl-pyrrolo[3,4-*d*]pyridazin-6-yl)-benzamide,
1,4,5,7-tetramethyl-pyrrolo[3,4-*d*]pyridazin-6-ylamine picrate,
1,4,5,7-tetramethyl-pyrrolo[3,4-*d*]pyridazin-6-ylamine,
5,7-dimethyl-6-phenyl-6*H*-pyrrolo[3,4-*d*]pyridazine,
5,7-dimethyl-2-phenacyl-6*H*-pyrrolo[3,4-*d*]pyridazinium bromide,
2-(2-methoxycarbonylvinyl)-5,7-dimethyl-6*H*-pyrrolo[3,4-*d*]pyridazinium tetrafluoroborate
5,7-diphenyl-6*H*-pyrrolo[3,4-*d*]pyridazine,
5,6,7-trimethyl-6*H*-pyrrolo[3,4-*d*]pyridazine,
1,4-diphenyl-7,8,9,10-tetrahydro-pyridazino[4,5-*a*]indolizine,
5-methyl-1,4-diphenyl-7,8,9,10-tetrahydro-pyridazino[4,5-*a*]indolizine,
6-benzyl-1,4-diphenyl-5-p-tolyl-6*H*-pyrrolo[3,4-*d*]pyridazine,
6-benzyl-5-(2-chloro-phenyl)-1,4-diphenyl-6*H*-pyrrolo[3,4-*d*]pyridazine,
1,4,5,6,7-pentaphenyl-6*H*-pyrrolo[3,4-*d*]pyridazine,
6,7,10,11-tetr phenyl-pyridazino[4',5':3,4]pyrrolo[1,2-*a*]quinoxaline,
11-(4-nitro-phenyl)-6,7,10-triphenyl-pyridazino[4',5':3,4]pyrrolo[1,2-*a*]quinoxaline,
6-benzyl-1,4,5-triphenyl-6*H*-pyrrolo[3,4-*d*]pyridazine,
9,12-diphenyl-pyridazino[4',5':3,4]pyrrolo[2,1-*a*]isoquinoline,
5-methylsulfanyl-1,4,6,7-tetraphenyl-6*H*-pyrrolo[3,4-*d*]pyridazine,
1,4,6,7-tetraphenyl-6*H*-pyrrolo[3,4-*d*]pyridazine-5-carboxylic acid ethyl ester,
7,10-diphenyl-pyridazino[4',5':3,4]pyrrolo[1,2-*a*]quinoline,
11,14-diphenyl-pyridazino[4',5':3,4]pyrrolo[1,2-*f*]phenanthridine,
1-oxo-7-oxy-6*b*,11*b*-dihydro(pyridazino[4',5'-*c*]-pyrrolo)[2,1-*c*]benzoxazine-1,4,
10-methyl-1,4-diphenyl-8,9-dihydro-7*H*-benzo(*ef*)pyridazino[4,5-*a*]cycl[3.3.2]azine,
11-methyl-1,4-diphenyl-7,8,9,10-tetrahydrocyclohepta(*ef*)pyridazino[4,5-*a*]cycl[3.3.2]azine,
1,4-dichloro-5,6,7-trimethyl-6*H*-pyrrolo[3,4-*d*]pyridazine,

1-chloro-4-ethoxy-5,6,7-trimethyl-6*H*-pyrrolo[3,4-*d*]pyridazine,
1-chloro-5,6,7-trimethyl-6*H*-pyrrolo[3,4-*d*]pyridazinium chloride,
1-ethoxy-2,5,6,7-tetramethyl-6*H*-pyrrolo[3,4-*d*]pyridazinium
tetrafluoroborate,
1-ethoxy-5,6,7-trimethyl-2*H*,6*H*-pyrrolo[3,4-*d*]pyridazinium tetrafluoroborate,
1-ethoxy-3-ethyl-5,6,7-trimethyl-6*H*-pyrrolo[3,4-*d*]pyridazinium
tetrafluoroborate,
1-ethoxy-5,6,7-trimethyl-6*H*-pyrrolo[3,4-*d*]pyridazine,
5-cyano-1,4-dimethylpyridazino[4,5-*a*]indolizine,
1,4-dimethyl-6-phenyl-2,3,8a-triaza-fluorene-9-carbonitrile,
6-benzoyl-1,4-dimethyl-2,3,8a-triaza-fluorene-9-carbonitrile,
6-benzyl-1,4-diphenyl-2,3,8a-triaza-fluorene-9-carbonitrile,
1,4,6-trimethyl-2,3,8a-triaza-fluorene-9-carbonitrile,
5-cyano-1,4-diphenylpyridazino[4,5-*a*]indolizine,
6-methyl-1,4-diphenyl-2,3,8a-triaza-fluorene-9-carbonitrile,
6-benzoyl-1,4-diphenyl-2,3,8a-triaza-fluorene-9-carbonitrile,
1,4,6-triphenyl-2,3,8a-triaza-fluorene-9-carbonitrile,
5,7-dimethyl-1,4-diphenyl-2,3,8a-triaza-fluorene-9-carbonitrile,
9,12-diphenyl-pyridazino[4',5':3,4]pyrrolo[2,1-*a*]isoquinoline-8-carbonitrile,
dimethyl 3,12,13,17-tetramethyl-7²,7³-diazabeno[g]porphyrin-2,18-
dipropionate,
5,6-dihydro-2,3-dimethoxypyridazino[4',5':3,4]pyrrolo[2,1-*a*]isoquinolin-9-
ol,
5,6-dihydro-2,3-dimethoxypyridazino[4',5':3,4]pyrrolo[2,1-*a*]isoquinolin-9-
ol-hydrochloride,
3-methyl-6,9-diphenylthiazolo[3',2':1,2]pyrrolo[3,4-*d*]pyridine, or
1,4-diphenylpyridazino[4',5':3,4]pyrrolo[2,1-*b*]benzothiazole; and
is not selected from the following table:

